Practice
Specialties
Hygiene
Clinical
Business
Cases
Careers
Tariffs
Sign In
Endodontics
Oral & Maxillofacial Surgery
Orofacial Pain
Orthodontics
Pediatrics
Periodontics
Smile Design
Analgesics: Page 23
NCI grant to fund head/neck cancer drug study
By
DrBicuspid.com staff writers
Researchers from Louisiana State University, the University of Chicago, and 13 other research institutions have been awarded a $1.24Â million National Cancer Institute (NCI) grant to evaluate an immunosuppressant drug's potential to prevent the recurrence of head and neck cancer.
September 25, 2011
Licorice shows promise in preventing oral diseases
By
Erin Archer, RN
Can a medicinal root that tastes like candy be used to prevent caries and treat alveolar bone loss in periodontal disease? A literature review in
Oral Diseases
found that licorice root appears to have many beneficial effects in the oral cavity, but the study authors caution that more clinical trials are needed.
September 20, 2011
DOCS Education updates sedation information website
By
DrBicuspid.com staff writers
DOCS Education has recently revamped SedationRegulations.com, a free website that summarizes each U.S. state or Canadian province's sedation dentistry regulations, to demystify sedation regulations for dentists.
September 12, 2011
Milestone Scientific CFO takes on new role
By
DrBicuspid.com staff writers
Milestone Scientific's chief financial officer (CFO) Joseph D'Agostino will also take on the role of chief operating officer.
September 11, 2011
FDA advisers consider time limit for bone drugs
By
Reuters Health
ADELPHI, Md. (Reuters) - U.S. health advisers are considering a time limit for taking a class of drugs used by millions of women to prevent bone fractures, due to concerns over unusual fractures linked to the medicines and possible higher cancer rates.
September 8, 2011
FDA panels want revised labels on bisphosphonate drugs
By
DrBicuspid.com staff writers
Manufacturers of bisphosphonate drugs such as Fosamax and Zometa should make changes to their product labeling to reduce the risk of bone fractures, two U.S. Food and Drug Administration (FDA) advisory panels concluded Friday.
September 8, 2011
FDA panels to review bisphosphonate risks
By
DrBicuspid.com staff writers
Two U.S. Food and Drug Administration (FDA) advisory panels will meet this week to review the potential risks associated with long-term use of bisphosphonate medications such as Fosamax and to determine whether these drugs are safe and effective when used longer than three to five years, according to a story in the
New York Times
.
September 5, 2011
Miconazole tablets effective on candidiasis
By
DrBicuspid.com staff writers
Miconazole buccal tablets are an effective treatment for oropharyngeal candidiasis, although the cost can be prohibitive for some patients, according to an article in the
Journal of Patient Preference and Adherence
.
August 25, 2011
Milestone Scientific Q2 revenues down 22%
By
DrBicuspid.com staff writers
A decline in international revenue had a negative impact on Milestone Scientific's second-quarter financials. The company reported revenues of $2.5 million for the second quarter of 2011 (end-June 30), down from revenues of $3.2 million for the second quarter of 2010.
August 15, 2011
Leaders in Dentistry: A conversation with Dr. Joel Weaver
By
Rob Goszkowski
Critical drug shortages, the safety of administering general anesthesia to very young patients, and state guidelines about which dentists can administer general anesthesia are all challenging aspects of dental anesthesiology.
DrBicuspid.com
spoke with Dr. Joel Weaver to get his perspective.
August 1, 2011
Oral bisphosphonates may up risk of esophageal cancer
By
DrBicuspid.com staff writers
The U.S. Food and Drug Administration is continuing to review data from published studies to evaluate whether the use of oral bisphosphonates is associated with an increased risk of esophageal cancer.
July 20, 2011
New Heraeus desensitizer gel enhances patient comfort
By
DrBicuspid.com staff writers
Heraeus Kulzer has introduced Gluma Desensitizer PowerGel, designed to promote patient comfort during prophies, especially for those who've experienced sensitivity due to receding gums.
July 19, 2011
Previous Page
Page 23 of 43
Next Page